更昔洛韦治疗病毒性口腔疱疹的有效性和安全性评价

Ef?cacy and Safety of Ganciclovir in the Treatment of Viral oral Herpes

目的:探析更昔洛韦应用于病毒性口腔疱疹中的治疗效果和安全性。方法:2017年11月—2018年11月在我院治疗病毒性口腔疱疹患儿中选取84例,严格按照系统随机分配原则分为对照组和观察组,各42例。其中对照组采用利巴韦林治疗,观察组采用更昔洛韦治疗,观察对比两组患者治疗效果、临床症状改善时间和不良反应发生率。结果:治疗后,对照组总有效率为78.57%,观察组总有效率为95.24%,对照组总有效率低于观察组;对照组口腔疼痛时间、体温恢复时间、溃疡消失时间及疱疹消失时间均长于观察组,且对照组不良反应发生率为11.90%,观察组无不良反应发生现象,对照组不良反应发生率高于观察组,差异具有统计学意义(P<0.05)。结论:予以病毒性口腔疱疹患儿更昔洛韦进行治疗,效果显著,可有效改善临床症状时间,降低不良反应发生率。

Objective: To explore the efficacy and safety of ganciclovir in the treatment of viral oral herpes. Methods: Eighty-four children with viral oral herpes were selected from November 2017 to November 2018 in our hospital, and divided into control group and observation group according to the principle of systematic random distribution, with 42 cases in each group. The control group was treated with ribavirin and the observation group with ganciclovir. Results: After treatment, the total effective rate of the control group was 78.57%, the total effective rate of the observation group was 95.24%, and the total effective rate of the control group was 95.24%. The effective rate was lower than that in the observation group. The oral pain time, temperature recovery time, ulcer disappearance time and herpes disappearance time in the control group were longer than those in the observation group, and the incidence of adverse reactions in the control group was 11.90%. There was no adverse reaction in the observation group. The incidence of adverse reactions in the control group was higher than that in the observation group, and the difference was statistically significant (P<0.05). Conclusion: Ganciclovir is effective in treating children with viral oral herpes. It can effectively improve the time of clinical symptoms and reduce the incidence of adverse reactions. It is worth popularizing.